Therapeutic heterocyclic compounds

Details Therapeutic heterocyclic compounds Therapeutic heterocyclic compounds

2006-05-16

2006-05-16

Raymond, Richard L. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S456000, C514S430000, C549S023000, C549S362000, C549S396000, C549S406000, C549S407000

Reexamination Certificate

active

07045514

ABSTRACT:
Provided herein is a compound having the formula (I):Wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1Band 5HT1Dantagonists.

REFERENCES:
patent: 3862143 (1975-01-01), Klutchko et al.
patent: 3937837 (1976-02-01), Klutchko et al.
patent: 4189498 (1980-02-01), Kabbe et al.
patent: 4307020 (1981-12-01), Kabbe et al.
patent: 5112856 (1992-05-01), Gaginella et al.
patent: 5171865 (1992-12-01), Kurono et al.
patent: 6153625 (2000-11-01), Peglion et al.
patent: 6552054 (2003-04-01), Yasuma et al.
patent: 0000377 (1979-01-01), None
patent: 0017578 (1980-10-01), None
patent: 0104018 (1984-03-01), None
patent: 0546389 (1993-06-01), None
patent: 2177084 (1987-01-01), None
patent: 2001-261657 (2001-09-01), None
patent: WO 9109853 (1991-07-01), None
patent: WO 9429293 (1994-06-01), None
patent: WO 9734883 (1997-09-01), None
patent: WO 9827058 (1998-06-01), None
patent: WO 9827080 (1998-06-01), None
patent: WO 9914207 (1999-03-01), None
patent: WO 9914212 (1999-03-01), None
patent: WO 9914213 (1999-03-01), None
patent: WO 0012623 (2000-03-01), None
patent: WO 0116127 (2001-03-01), None
Chemical abstract DN 128:265746, also cited as Berg et al, J. Med. Chem. Behavioral & Biochem. Pharmacology & Mol. Chem. 41/11, 1934-42(1998).
Barnes, et al., “A review of central 5-HT receptors and their funciton”, Neuropharmacology 38, 1083-1152, (1999).
Berg, et al., “(R)-(+)-2-[[[3-(Morpholinomethyl)-2H-chromen-8-yl]oxy]methyl]morpholine Methanesulfonate: A new selective rat 5-Hydroxytryptamine1B receptor antagonist”, J. Med. Chem. vol. 41, 1934-1942 (1998).
Clitherow, et al., “Evolution of an novel series of . . . antogonists”, Journal of Medicinal Chemistry, vol. 34, No 15 2253-2257.
Cryan, et al., “5-HT1A and Beyond: The Role of Serotonin and its Receptors in Depresion and the Antidepressant Response”, Hum. Psychopharmacol. Clin. Exp., 15, 113-115 (2000).
Gaster, et al., “The Selective 5HT1b Receptor Inverse Agonist . . . (SB-224289) Potently Blocks Terminal 5-HT Autoreceptor Function Both in Vitro and in Vivo” J. Med. Chem., 41, 1218-1235 (1998).
Halazy, et al., “5-HT1B/1D antagonists and depression”, Exp. Opin. Ther. Patents, 7(4) 339352 (1997).
Massot, et al., “5-HT1B Receptors: A Novel Target for Lithium”, Neuropsychopharmacology vol. 21, No. 4, 530-541.
Raposo, et al., “The effect of chromenone receptors on the selectivity of the reaction between pyrrolidine and 5-Hydroxymethyl-2-(5H)-furanone”, Chemistry Letters, 173-174 (1997).
Russel, et al., “3-[3-(piperidin-1-yl)propyl]indoles as Highly Selective h5-HT1D Receptor Agonist”, J. Med. Chem., 42, 4981-5001, (1999).

Affiliated with

Also associated with

Rating

Therapeutic heterocyclic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic heterocyclic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic heterocyclic compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3609195